Forsite Capital Closes Sixth Fund, focusing on Healthcare and Life Science Startups

Foresite Capital , a multi-stage healthcare and life sciences investment firm continues to do what they do best—investing in companies that leverage biology and big data to transform healthcare.

With the recent closing of its Sixth fund of $900 million, the firm stands on a record of 47 IPOs, 28 mergers and acquisitions, and 58 FDA drug approvals since its founding in 2011.

With over $3.5 billion now under management, Foresite’s team adheres to a data and science-driven investment strategy. They fund promising healthcare and life sciences businesses at all stages of their life cycles, specifically seeking opportunities to fill unmet medical needs.

“Fund VI is deploying capital into what I believe is one of the best biotech investment environments of my career,” said Jim Tananbaum , founder and CEO of Foresite Capital. “Advances in biology, genomics, and artificial intelligence continue to converge. Biotech innovation is predicting, preventing, and treating disease more effectively than ever before. We believe these advances will lead to increasingly efficient investing at all stages.”

Funding is one part of what Foresite brings to its portfolio companies. They provide high-level support to founders of their growth-oriented companies, offering strategic guidance and technical assistance. The team leverages its expertise in company formation, therapeutic product development, and data science/machine learning.

Fund VI’s limited partners include a range of investors, among them university endowments, charitable foundations, medical institutions, pension funds, insurance companies, private banks, and family offices worldwide.

“We’re grateful for the support we’ve received from both long-standing partners and new investors alike,” said Hadi Tabbaa , Managing Director and Head of Investor Relations and Business Development. “Their partnership with Foresite Capital enables our support of entrepreneurs who are addressing some of the most vexing aspects of our healthcare system and improving the lives of patients.”